KFAS
CORT icon

Keating Financial Advisory Services’s Corcept Therapeutics CORT Stock Holding History

Keating Financial Advisory Services’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.65K Buy
111
+1
+0.9% +$60 ﹤0.01% 1262
2026
Q1 		$4.43K Buy
110
+68
+162% +$2.54K ﹤0.01% 1507
2025
Q4 		$1.46K Buy
+42
New +$3.3K ﹤0.01% 1687

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's CORT Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Corcept Therapeutics (CORT) stake by 0.91% in Q2 2026, buying an estimated $60 and bringing the position to 111 shares worth $9.65K. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

Keating Financial Advisory Services first reported a position in CORT in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Keating Financial Advisory Services held 111 shares of Corcept Therapeutics worth $9.65K as of Q2 2026.
  • Keating Financial Advisory Services bought 1 Corcept Therapeutics share in Q2 2026, an estimated $60.
  • Corcept Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1262 holding.
  • Keating Financial Advisory Services first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.